Subscribe
shutterstock_309001163_bill_perry
Bill Perry / Shutterstock.com
21 January 2021Americas

Federal Circuit agrees with PTAB in optical patent appeal

The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board (PTAB) which centered on the validity of a patent for an ophthalmic illuminator.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
AbbVie Humira patent invalidated by PTAB
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.
Americas
Allergan and tribe claim PTAB can’t decide on Restasis patents
13 March 2018   Allergan and the Saint Regis Mohawk Tribe have argued that the Patent Trial and Appeal Board doesn’t have the jurisdiction to decide on the validity of patents concerning a dry-eye treatment while its recent decision is being appealed.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

More on this story

Americas
AbbVie Humira patent invalidated by PTAB
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.
Americas
Allergan and tribe claim PTAB can’t decide on Restasis patents
13 March 2018   Allergan and the Saint Regis Mohawk Tribe have argued that the Patent Trial and Appeal Board doesn’t have the jurisdiction to decide on the validity of patents concerning a dry-eye treatment while its recent decision is being appealed.

More on this story

Americas
AbbVie Humira patent invalidated by PTAB
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.
Americas
Allergan and tribe claim PTAB can’t decide on Restasis patents
13 March 2018   Allergan and the Saint Regis Mohawk Tribe have argued that the Patent Trial and Appeal Board doesn’t have the jurisdiction to decide on the validity of patents concerning a dry-eye treatment while its recent decision is being appealed.

More features

UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Bristol Myers Squibb leader named INTA 2025 president
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks